NasdaqGS - Nasdaq Real Time Price USD
BioCryst Pharmaceuticals, Inc. (BCRX)
10.08
-0.19
(-1.85%)
At close: May 7 at 4:00:00 PM EDT
10.05
-0.03
(-0.30%)
After hours: May 7 at 7:57:51 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 7 |
| Avg. Estimate | 0.07 | 0.05 | 0.2 | 0.52 |
| Low Estimate | 0 | 0 | 0 | 0.26 |
| High Estimate | 0.23 | 0.13 | 0.35 | 0.85 |
| Year Ago EPS | -0.06 | -0.07 | -0.42 | 0.2 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 11 | 11 |
| Avg. Estimate | 149.53M | 156.71M | 613.36M | 703.14M |
| Low Estimate | 143.07M | 153.75M | 600.13M | 656.32M |
| High Estimate | 156.02M | 158.6M | 629.89M | 751M |
| Year Ago Sales | 109.33M | 117.08M | 450.71M | 613.36M |
| Sales Growth (year/est) | 36.77% | 33.85% | 36.09% | 14.64% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.16 | -0.08 | -0.06 | -0.05 |
| EPS Actual | -0.06 | -0.07 | -0.13 | 0 |
| Difference | 0.1 | 0.01 | -0.07 | 0.05 |
| Surprise % | 63.28% | 17.42% | -115.27% | 100.00% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0.07 | 0.05 | 0.2 | 0.52 |
| 7 Days Ago | -0.01 | -0 | -0.05 | 0.32 |
| 30 Days Ago | -0.01 | -0 | -0.06 | 0.32 |
| 60 Days Ago | -0.01 | -0 | -0.07 | 0.32 |
| 90 Days Ago | -0.01 | -0.02 | -0.06 | 0.32 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 1 | 1 |
| Up Last 30 Days | 1 | 2 | 2 | 2 |
| Down Last 7 Days | -- | 1 | 1 | 1 |
| Down Last 30 Days | -- | 1 | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| BCRX | 218.05% | 177.17% | 147.71% | 160.00% |
| S&P 500 | 12.50% | 3.24% | 7.95% | 13.84% |
Upgrades & Downgrades
| Maintains | Barclays: Equal-Weight to Equal-Weight | 5/7/2025 |
| Reiterates | RBC Capital: Outperform to Outperform | 5/6/2025 |
| Maintains | JP Morgan: Overweight to Overweight | 5/6/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/6/2025 |
| Maintains | Needham: Buy to Buy | 5/6/2025 |
| Initiated | Cantor Fitzgerald: Overweight | 4/29/2025 |
Related Tickers
RGC Regencell Bioscience Holdings Limited
189.99
+25.82%
SXTC China SXT Pharmaceuticals, Inc.
1.9000
-7.32%
NBIX Neurocrine Biosciences, Inc.
121.61
+2.26%
TEVA Teva Pharmaceutical Industries Limited
17.60
+9.18%
PTPI Petros Pharmaceuticals, Inc.
0.1478
-24.97%
ESPR Esperion Therapeutics, Inc.
0.8709
-10.72%
ALKS Alkermes plc
30.38
+0.07%
ZTS Zoetis Inc.
155.99
+4.08%
KNSA Kiniksa Pharmaceuticals International, plc
26.77
-0.63%
AKBA Akebia Therapeutics, Inc.
2.4600
+6.03%